Dean J. Mitchell

This profile gathers the share dealings of Dean J. Mitchell across 4 companies, led by Precigen, Inc., Theravance Biopharma, Inc. and ImmunoGen, Inc. Between 3 September 2021 and 23 September 2026, the trades on record add up to 20 filings.

No open-market sale appears; the market trades are 3 purchases worth €114k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 7 share grants and 7 option exercises.

The median purchase comes to €39k. Clusters matter here: 2 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 24 September 2026: a transaction, in Theravance Biopharma, Inc. The clock since the last published purchase (25 September 2023) now reads 1,119 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.